简单疹病毒感染与阿尔茨海默病生物标志物之间的关联:在MAPT试验中的分析
Morgane Linard1, Isabelle Garrigue2,3, Bruno Vellas4,5
1INSERM U1219 Bordeaux Population Health Research Center, University of Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France. morgane.linard@gmail.com.
Scientific reports
|January 17, 2025
概括
简单疹病毒1 (HSV-1) 感染与大脑中较低的粉样蛋白沉积物有关,特别是在APOE4载体中. 这是阿尔茨海默病中意想不到的发现.
科学领域:
- 神经科学是一个神经科学.
- 传染性疾病 传染性疾病
- 老年学是指老年学的学科.
背景情况:
- 之前的体外和动物研究表明,单纯疹病毒1 (HSV-1) 可能导致阿尔茨海默病 (AD) 病理,包括粉样质沉积和高酸化.
- HSV-1感染在人类AD病变发生过程中的作用尚不清楚,有关其与关键AD生物标志物相关的证据相互矛盾.
研究的目的:
- 调查HSV-1感染和阿尔茨海默病生物标志物之间的关联,在一个有认知能力下降风险的人群中.
- 通过APOE4基因型和HSV-1重新激活频率来探索这种关联的潜在修改.
主要方法:
- 对182名来自多域阿尔茨海默氏症预防试验的参与者的横截面研究.
- 通过正子发射断层扫描 (PET) 扫描评估HSV-1血清学和皮质粉样蛋白负载.
- 在亚样本中分析了血Aβ42/40比率,神经纤维光链和p-tau181.
- 根据APOE4基因型分层的多变量线性回归.
主要成果:
- 在研究样本中观察到HSV-1感染的高患病率 (85.2%).
- 感染HSV-1的参与者表现出较低皮质粉样蛋白负载的趋势 (p=0.06),这在那些抗HSV-1IgG水平较高的人群中显著 (p=0.04).
- 这种关联仅在APOE4载体 (p=0.01) 中显著,显示出粉样蛋白负担减少.
- 在HSV-1感染和血AD生物标志物之间没有发现显著的关联.
结论:
- 与体外发现相反,人类的HSV-1感染与皮质粉样蛋白负载较低有关,特别是在APOE4载体中.
- 观察到的关联可能归因于免疫反应的改变,有利于粉样蛋白清除或潜在的选择偏差.
- 需要进一步的研究来阐明HSV-1,APOE4基因型和阿尔茨海默病病理生理学之间的复杂相互作用.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
18.9K
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
